Key result
Novel molecule SCR2682 potently activates neuronal Kv7 channels and reverses epileptic seizures in rodents.
Why the study?
Activation of neuronal Kv7/KCNQ/M-current represents an attractive therapeutic strategy for hyperexcitability-related neuropsychiatric disorders, representing an unmet medical need.
Does SCR2682 activate neuronal Kv7 channels and inhibit seizures in preclinical models?
Does SCR2682 activate neuronal Kv7 channels and inhibit seizures in preclinical models?
SCR2682 is a novel, potent neuronal Kv7 channel opener that reverses epileptic seizures in rodents, suggesting potential for antiepileptic therapy development.
Authors
No takes yet. Share an insight, caveat, or question.
SCR2682 shows promise in rodent epilepsy models; leaves open translation to clinical antiepileptic use.
Zhang et al. (2019) studied Epilepsy. SCR2682 vs. Retigabine was evaluated on Activation of Kv7.2/Kv7.3 channels and inhibition of seizures. The novel small molecule SCR2682 selectively and potently activates neuronal Kv7 channels (EC50 9.8 nM) and reverses epileptic seizures in rodents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: